AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06359353
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision.
Trial: NCT01730222
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin at 30 mg/m2 on days 1 and 15
Trial: NCT01730222
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
Trial: NCT01730222
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
Trial: NCT00379639
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
Trial: NCT00825487
Drug: ARQ 621
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
Trial: NCT00379639
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
Trial: NCT01318460
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
Trial: NCT04085289
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT03317015
Drug: triamcinolone XRG5029
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: spray solution~Route of administration: nasal
Trial: NCT03317015
Drug: fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: spray solution~Route of administration: nasal
Trial: NCT00207025
Drug: BMS-275183
RxNorm normalized name: BMS-275183
DrugBank: BMS-275183 (DB12144)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02406508
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03212781
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total dose infusion
Trial: NCT03212781
Drug: Ferrous Fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT02124317
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
Trial: NCT02124317
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
Trial: NCT03849508
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Trial: NCT04301804
Drug: SHR6390
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a selective small-molecule CDK4/6 inhibitor
Trial: NCT02369796
Drug: TAK-448
RxNorm normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 solution for subcutaneous injection
Trial: NCT01131689
Drug: sorafenib, TS-1
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
Trial: NCT03805282
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion, variable dose of lidocaine.
Trial: NCT00392769
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
Trial: NCT02561832
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablets taken orally twice daily
Trial: NCT02561832
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injections on day one of each cycle
Trial: NCT04239391
Drug: Triferic
RxNorm normalized name: Triferic
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric Pyrophosphate Citrate
Trial: NCT00499083
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
Trial: NCT00499083
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Trial: NCT00048438
Drug: paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03285763
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Trial: NCT03644511
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prescribed by physician.
Trial: NCT03644511
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescribed by physician.
Trial: NCT02222948
Drug: Vatelizumab
RxNorm normalized name: Vatelizumab
DrugBank: Vatelizumab (DB12346)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Trial: NCT04238364
Drug: EI-1071
RxNorm normalized name: EI-1071
DrugBank: EI-1071 (DB18486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EI-1071 Tablet(s)
Trial: NCT02147132
Drug: Nicotine Nasal Spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days. 1 mg/dose, up to 40x/day.
Trial: NCT02147132
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
Trial: NCT02147132
Drug: Placebo Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
Trial: NCT02665754
Drug: Rescue medication for allergic rhinitis
RxNorm normalized name: catfish allergenic extract
DrugBank: Catfish (DB14758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
Trial: NCT00252668
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005035
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01680471
Drug: Midazolam 0.03mg/kg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Trial: NCT01680471
Drug: Midazolam 0.05mg/kg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Trial: NCT01052701
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)
Trial: NCT01052701
Drug: Ribavirin plus Abacavir (ABC)
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours
Trial: NCT01538667
Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
Trial: NCT01538667
Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
Trial: NCT01538667
Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
Trial: NCT01538667
Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
Trial: NCT04571567
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
Trial: NCT02780752
Drug: hymecromone
RxNorm normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Hymecromone
Trial: NCT01855594
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg/tablet, 6 weeks course of oral administration
Trial: NCT00213486
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02689713
Drug: Voriconazole (topical)
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
Trial: NCT02689713
Drug: Topical Sterile Water Placebo Group
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
Trial: NCT01563809
Drug: FSH+LH
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 IU of LH will be given from stimulation day 1
Trial: NCT01896518
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00060840
Drug: Nitrogen
RxNorm normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrogen (N2) administered at 40 ppm for 48 hours
Trial: NCT01388335
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01388335
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02293317
Drug: TIV
RxNorm normalized name: Ultiva
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HA based seasonal influenza vaccine, for 2014/15 seson
Trial: NCT04152941
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
Trial: NCT00125164
Drug: rhIGF-1 (mecasermin, Tercica, Inc.)
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice Daily Injection
Trial: NCT00670306
Drug: Cetrorelix Pamoate
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
Trial: NCT04730232
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
Trial: NCT04730232
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Trial: NCT01470118
Drug: alcaftadine 0.25% ophthalmic solution
RxNorm normalized name: Alcaftadine 0.25% Ophthalmic Solution
DrugBank: Alcaftadine (DB06766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Trial: NCT01470118
Drug: olopatadine 0.2% ophthalmic solution
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Trial: NCT01470118
Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of placebo instilled in each eye at Day 0 and Day 14.
Trial: NCT01009216
Drug: ABT-384
RxNorm normalized name: ABT-384
DrugBank: ABT-384 (DB12501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses will be administered daily for 5 days.
Trial: NCT00338585
Drug: alfimeprase
RxNorm normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04623632
Drug: Transversus abdominus plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transversus abdominus plane block using 40 ml of bupivacaine 0.25%
Trial: NCT04472832
Drug: Mitapivat 100 mg
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 50-mg tablets
Trial: NCT04472832
Drug: Mitapivat 300 mg
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six 50-mg tablets
Trial: NCT01146795
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
Trial: NCT01146795
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
Trial: NCT01146795
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
Trial: NCT03636893
Drug: FLOT Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU+Leucovorin+Docetaxel+Oxaliplatin
Trial: NCT03636893
Drug: SOX Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
Trial: NCT01896518
Drug: Tobacco lozenge
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00453336
Drug: Porfimer Sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
Trial: NCT00151775
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily
Trial: NCT00151775
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg
Trial: NCT01396252
Drug: BMS-820836
RxNorm normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0.5 mg, Once daily, 14 days
Trial: NCT01396252
Drug: BMS-820836
RxNorm normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 1 mg, Once daily, 14 days
Trial: NCT01396252
Drug: BMS-820836
RxNorm normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 2 mg, Once daily, 14 days
Trial: NCT01396252
Drug: Placebo matching BMS-820836
RxNorm normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 14 days
Trial: NCT01396252
Drug: BMS-820836
RxNorm normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
Trial: NCT00856570
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00856570
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04885777
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution.